Iniversity Hospitals Birmingham

Current evidence for potential biomarkers and are not currently clinically approved



number of people in study



Birmingham Health Partners

Issue#: MAY V6.03 Date: 05MAY2020

ardiac troponin

Source: Tersalvi et al., Journal of Cardiac Failure, 2020; Lippi et al., Prog Cardiovasc Dis, 2020; Huang et al., Lancet, 2020; Han et al., medRxiv, 2020; Guo et al., JAMA, 2020

in severe COVID-19

heart damage raises troponin levels

(and may explain increased mortality in COVID-19)

those with troponin were:

older, comorbid, more likely to be admitted to ICU and to die

ւ187

troponin in 28% of patients

341

↑troponin (25.6ng/L) in severe patients

↑troponin in 5 patients with cardiac injury

troponin in severe cases upon admission

D-dimer

Source: Yao et al., Research Square, 2020; Yu et al., Research Square, 2020; Huang et al., Lancet, 2020; Han et al., medRxiv, 2020; Tang et al., J Thromb Haemost, 2020; Wang et al., JAMA, 2020; Zhou et al., Lancet, 2020

in severe COVID-19

>2mg/L reported in most studies

clot breakdown increases levels of d-dimers (D-D)

◆ D-dimer in 75% of patients, where >2.14mg/L predicted

mortality

◆ D-dimer in COVID-19 vs CAP, (decreased with treatment)

◆ D-dimer in ICU patients 2.4mg/L vs **0.5mg/L** (4 days post admission)

D-dimer in severe patients nogu admission

D-dimer in severe 2.12mg/L vs mild 0.61mg/L

◆ D-dimer in severe 4.14mg/L vs mild 1.66mg/L

D-dimer in those who died 5.2mg/L vs survived 0.6mg/L

ymphocyte Count

Source: **Han et al.**, medRxiv, 2020; **Yang et al.**, medRxiv, 2020; **Guan et al.**, New Engl J Med, 2020; **Ruan et al.**, Intensive Care Medicine, 2020

in severe COVID-19

and appears to predict severity and mortality

Lymphocytes move to lymph nodes during viral infection

↓ lymphocytes

counts below 1.045x109/L identified severe patients

Lymphopenia

in 80% of severe patients

1099

Lymphopenia in 83% of all admitted patients, but worse in

severe patients

150

↓ lymphocytes in those that died (0.6x109/L) vs discharged (1.42x10°/L) (but were also older)

Blood II-6

Source: Herold et al., medRxiv, 2020; Gao et al., J Med Virol, 2020

0 0 Released by immune cells

infection

during

in severe COVID-19

>80pg/mL associated with mechanical ventilation and 92% risk of respiratory failure

↑IL-6 in severe (36pg/mL) vs mild (11pg/mL)

Source: Han et al., medRxiv, 2020; Zhang et al., Eur Radiol, 2020

LDH

LDH converts lactate to pyruvate and is a marker of tissue damage

in severe COVID-19

serum LDH

in severe patients >283U/L and correlated with clinical severity, APACHE II and SOFA scores

↑serum LDH in severe patients with 70% >250U/L (odds ratio 2.5)

-ibrinogen

Source: Spiezia et al., Coagulation and Fibrinolysis, 2020; Wang et al., Lancet, 2020; Gao et al., J Med Virol, 2020

in severe COVID-19

♦fibrinogen in severe patients 517mg/dL vs healthy 297mg/dL (healthy not in ICU)

fibrinogen

in severe patients (but unclear severity)

♠ fibrinogen in severe patients 3.84g/L vs mild

3.11xg/L

Source: **Huan et al.**, Journal of Infection, 2020

hepatocytes

SAA

SAA is released by hepatocytes, recruits immune cells and has anti-microbial effects

in severe COVID-19

and CRP in all COVID-19 patients (no control group comparison) and correlated with disease progression and poor CT scan



UNIVERSITYOF Generated in collaboration with researchers at the University of Birmingham. This is not a clinical guideline or SOP. BIRMINGHAM Underlying COVID-19 disease presented in accompaning report.